Clinical aspects of hepatitis B virus infection

The Lancet

Volumn 342, Issue 8883, 1993, Pages 1340-1344

  Wright, T L ^a,b   Lau, J Y N ^c  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Section of Hepatobiliary Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; BETA INTERFERON; CORTICOSTEROID; FIALURIDINE; FOSCARNET; GAMMA INTERFERON; LAMIVUDINE; LEVAMISOLE; NUCLEOSIDE DERIVATIVE; RIBAVIRIN; THYMOSIN; VIDARABINE; ZIDOVUDINE;

CLINICAL PRACTICE; DRUG TOXICITY; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

ADULT; AGE FACTORS; BIOLOGY; BLOOD SUPPLY; CHRONIC DISEASES; DELIVERY OF HEALTH CARE; DEMOGRAPHIC FACTORS; DISEASES; DRUGS; EQUIPMENT AND SUPPLIES; HEALTH; HEALTH SERVICES; HEPATIC EFFECTS; HEPATITIS--TRANSMISSION; HISTOLOGY; HIV INFECTIONS; IMMUNIZATION; INFECTIONS; LIVER CIRRHOSIS; LIVER NEOPLASMS; NEOPLASMS; OBSTACLES; ORGANIZATION AND ADMINISTRATION; PHYSIOLOGY; POPULATION; POPULATION CHARACTERISTICS; PRIMARY HEALTH CARE; REPRODUCTIVE TRACT INFECTIONS; SEXUALLY TRANSMITTED DISEASES; SIGNS AND SYMPTOMS; TREATMENT; VACCINATION; VIRAL DISEASES;

CHRONIC DISEASE; CLINICAL TRIALS; HEPATITIS B; HIV INFECTIONS; HUMAN; INTERFERONS; LIVER TRANSPLANTATION; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027524806     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)92250-W     Document Type: Article

References (49)

1. The natural history of asymptomatic hepatitis B surface antigen carriers
2. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection
3. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy
4. Survival in chronic hepatitis B: an analysis of 397 patients
5. Hepatic tumours
6. Risk factors for hepatocellular carcinoma among patients with chronic liver disease
7. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies
8. Hepatitis B virus: a comprehensive strategy of eliminating transmission in the United States through universal childhood vaccination: recommendations of the Immunization Practices Advisory Committee (ACIP)
9. Hepatitis B immunization strategies: expanding the target
10. Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation
11. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis
12. Randomized controlled trial of recombinant human alpha interferon in patients with chronic hepatitis B
13. Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection
14. A randomized controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B
15. Interferon alfa therapy in patients with chronic hepatitis B virus infection: effects of hepatitis B virus DNA in the liver
16. Which patients with chronic hepatitis B virus infection will respond to α-interferon therapy? a statistical analysis of predictive factors
17. Treatment of chronic hepatitis B with interferon: experience with Asian patients
18. Long-term remission of chronic hepatitis B after alpha-interferon therapy
19. Interferon alfa for patients with clinically apparent cirrhosis due to chronic HBV
20. Effect of alpha-interferon in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis
21. Beta- and gamma-interferon in chronic active hepatitis B: a pilot trial of short-term combination therapy
22. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial
23. Levamisole and interferon in children with chronic hepatitis B
24. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B
25. FIAU, a new oral anti-viral agent, profoundly inhibits HBV DNA in patients with chronic hepatitis B
26. Pilot study of ribavarin and interferon-β for chronic hepatitis B
27. Treatment of patients with chronic type B hepatitis and concurrent human immunodeficiency virus infection with a combination of interferon alpha and azidothymidine: a pilot study
28. Phase II trial of lamivudine for chronic hepatitis B
29. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease
30. Hepatitis B virus reinfection after orthotopic liver transplantation
31. Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients
32. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus pre-core mutant
33. Hepatitis B virus core antigen (HBcAg). accumulation in an HBV nonproducer clone of HepG2-transfected cells is associated with cytopathic effect
34. Fibrosing cytolytic liver failure secondary to recurrent hepatitis B after liver transplanation
35. Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis
36. High-level expression of hepatitis B viral antigens in fibrosing cholestatic hepatitis
37. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice
38. Characterization and biologic properties of a hepatitis B virus isolated from a patient without hepatitis B virus serologic markers
39. Hepatitis B virus and apparent non-A, non-B hepatitis
40. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area
41. Persistence of hepatitis B viral DNA after serological recovery from hepatitis B virus infection
42. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients: a prospective study of 90 patients
43. Viral genetic variation: hepatitis B virus as a clinical example
44. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis
45. Interactions between human immunodeficiency virus 1, hepatitis delta virus and hepatitis B virus infections in 260 chronic carriers of hepatitis B virus
46. Hepatitis D virus and human immunodeficiency virus antibodies in parenteral drug abusers who are hepatitis B surface antigen positive
47. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival
48. Outcome of hepatitis B virus infection in homosexual men and its relation to prior human immunodeficiency virus infection